PLIANT THERAPEUTICS INC (PLRX) Stock Price & Overview
NASDAQ:PLRX • US7291391057
Current stock price
The current stock price of PLRX is 1.35 USD. Today PLRX is up by 2.27%. In the past month the price increased by 4.65%. In the past year, price increased by 0.75%.
PLRX Key Statistics
- Market Cap
- 83.579M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.44
- Dividend Yield
- N/A
PLRX Stock Performance
PLRX Stock Chart
PLRX Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PLRX. When comparing the yearly performance of all stocks, PLRX turns out to be only a medium performer in the overall market: it outperformed 47.63% of all stocks.
PLRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PLRX. While PLRX seems to be doing ok healthwise, there are quite some concerns on its profitability.
PLRX Earnings
PLRX Forecast & Estimates
11 analysts have analysed PLRX and the average price target is 2.72 USD. This implies a price increase of 101.48% is expected in the next year compared to the current price of 1.35.
PLRX Groups
Sector & Classification
PLRX Financial Highlights
Over the last trailing twelve months PLRX reported a non-GAAP Earnings per Share(EPS) of -2.44. The EPS increased by 29.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.03% | ||
| ROE | -94.04% | ||
| Debt/Equity | 0.14 |
PLRX Ownership
PLRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| ZTS | ZOETIS INC | 16.66 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PLRX
Company Profile
Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2020-06-03. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
Company Info
IPO: 2020-06-03
PLIANT THERAPEUTICS INC
331 Oyster Point Boulevard
South San Francisco CALIFORNIA 94080 US
CEO: Bernard Coulie
Employees: 49
Phone: 16504816770
PLIANT THERAPEUTICS INC / PLRX FAQ
What does PLIANT THERAPEUTICS INC do?
Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2020-06-03. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.
What is the stock price of PLIANT THERAPEUTICS INC today?
The current stock price of PLRX is 1.35 USD. The price increased by 2.27% in the last trading session.
Does PLIANT THERAPEUTICS INC pay dividends?
PLRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of PLRX stock?
PLRX has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting PLRX stock to perform?
11 analysts have analysed PLRX and the average price target is 2.72 USD. This implies a price increase of 101.48% is expected in the next year compared to the current price of 1.35.
How is the valuation of PLIANT THERAPEUTICS INC (PLRX) based on its PE ratio?
PLIANT THERAPEUTICS INC (PLRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.44).